MétaCan
Menu
Back to cohort
Record W2069659635 · doi:10.1007/s10549-013-2416-2

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

2013· article· en· W2069659635 on OpenAlexfundno aff
Miguel Martín, Aleix Prat, Álvaro Rodríguez-Lescure, Rosalía Caballero, Mark Ebbert, Blanca Munárriz, Manuel Ruíz‐Borrego, Roy R. L. Bastien, M. Carmen Crespo, Carole Davis, César A. Rodríguez, José Manuel López-Vega, Vicente Furió, Ana M. García, Maribel Casas, Matthew J. Ellis, Donald A. Berry, Brandelyn N. Pitcher, Lyndsay N. Harris, Amparo Ruı́z, Eric P. Winer, Clifford A. Hudis, Inge J. Stijleman, David Tuck, Eva Carrasco, Charles M. Perou, Philip S. Bernard

Bibliographic record

VenueBreast Cancer Research and Treatment · 2013
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsnot available
FundersBC Cancer AgencyU.S. Public Health ServiceUniversitat de BarcelonaUniversitat Autònoma de BarcelonaNational Cancer InstituteNational Institutes of HealthSociedad Española de Oncología MédicaVancouver Coastal Health Research InstituteBreast Cancer Research Foundation
KeywordsMedicinePaclitaxelInternal medicineOncologyBreast cancerAnthracyclineClinical endpointChemotherapyProportional hazards modelAdjuvantClinical trialRandomized controlled trialCancer

Abstract

fetched live from OpenAlex

To identify a group of patients who might benefit from the addition of weekly paclitaxel to conventional anthracycline-containing chemotherapy as adjuvant therapy of node-positive operable breast cancer. The predictive value of PAM50 subtypes and the 11-gene proliferation score contained within the PAM50 assay were evaluated in 820 patients from the GEICAM/9906 randomized phase III trial comparing adjuvant FEC to FEC followed by weekly paclitaxel (FEC-P). Multivariable Cox regression analyses of the secondary endpoint of overall survival (OS) were performed to determine the significance of the interaction between treatment and the (1) PAM50 subtypes, (2) PAM50 proliferation score, and (3) clinical and pathological variables. Similar OS analyses were performed in 222 patients treated with weekly paclitaxel versus paclitaxel every 3 weeks in the CALGB/9342 and 9840 metastatic clinical trials. In GEICAM/9906, with a median follow up of 8.7 years, OS of the FEC-P arm was significantly superior compared to the FEC arm (unadjusted HR = 0.693, p = 0.013). A benefit from paclitaxel was only observed in the group of patients with a low PAM50 proliferation score (unadjusted HR = 0.23, p < 0.001; and interaction test, p = 0.006). No significant interactions between treatment and the PAM50 subtypes or the various clinical-pathological variables, including Ki-67 and histologic grade, were identified. Finally, similar OS results were obtained in the CALGB data set, although the interaction test did not reach statistical significance (p = 0.109). The PAM50 proliferation score identifies a subset of patients with a low proliferation status that may derive a larger benefit from weekly paclitaxel.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.067
Threshold uncertainty score0.971

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.327
Teacher spread0.298 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations102
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueBreast Cancer Research and TreatmentSame topicBreast Cancer Treatment StudiesFrench-language works237,207